DE4310643A1
(de)
*
|
1993-04-01 |
1994-10-06 |
Merck Patent Gmbh |
Cyclische Adhäsionsinhibitoren
|
US5753230A
(en)
*
|
1994-03-18 |
1998-05-19 |
The Scripps Research Institute |
Methods and compositions useful for inhibition of angiogenesis
|
US5945403A
(en)
*
|
1997-05-30 |
1999-08-31 |
The Children's Medical Center Corporation |
Angiostatin fragments and method of use
|
US5837682A
(en)
|
1996-03-08 |
1998-11-17 |
The Children's Medical Center Corporation |
Angiostatin fragments and method of use
|
US6949511B1
(en)
|
1994-04-26 |
2005-09-27 |
The Children's Medical Center Corporation |
Methods of inhibiting angiogenesis via increasing in vivo concentrations of kringle region fragments of plasminogen
|
US6660842B1
(en)
|
1994-04-28 |
2003-12-09 |
Tripep Ab |
Ligand/receptor specificity exchangers that redirect antibodies to receptors on a pathogen
|
DE69531187T2
(de)
*
|
1994-12-20 |
2004-04-22 |
Merck Patent Gmbh |
Monoklonaler Antikörper gegen das Alpha-V-Integrin
|
US6440729B1
(en)
|
1995-06-30 |
2002-08-27 |
University Of Kansas Medical Center |
Treating angiogenesis-mediated diseases with the α2 monomer of type IV collagen
|
US6358735B1
(en)
|
1995-06-30 |
2002-03-19 |
University Of Kansas Medical Center |
Method for inhibiting angiogenesis and tumors with the isolated NC1 α3 chain monomer of type IV collagen
|
SK18898A3
(en)
*
|
1995-08-14 |
1998-07-08 |
Scripps Research Inst |
Method compositions useful for inhibition of 'alpha'v'beta'5 mediated angiogenesis
|
EP0850221B1
(de)
|
1995-08-30 |
2001-07-18 |
G.D. Searle & Co. |
Meta-guanidine, harnstoff, thioharnstoff oder azacyklische aminobenzoesäure-derivate als integrin antagonisten
|
US6100423A
(en)
*
|
1995-08-30 |
2000-08-08 |
G. D. Searle & Co. |
Amino benzenepropanoic acid compounds and derivatives thereof
|
US6346510B1
(en)
|
1995-10-23 |
2002-02-12 |
The Children's Medical Center Corporation |
Therapeutic antiangiogenic endostatin compositions
|
US5854205A
(en)
*
|
1995-10-23 |
1998-12-29 |
The Children's Medical Center Corporation |
Therapeutic antiangiogenic compositions and methods
|
KR19990066981A
(ko)
|
1995-10-23 |
1999-08-16 |
윌리엄 뉴우 |
치료용 맥관형성억제 조성물 및 방법
|
US5854221A
(en)
*
|
1996-12-12 |
1998-12-29 |
The Children's Medical Center Corporation |
Endothelial cell proliferation inhibitor and method of use
|
DE69727582T2
(de)
*
|
1996-08-15 |
2004-12-23 |
Novartis Ag |
Test zur quantifizierung von arthritiszustanden
|
GB9708265D0
(en)
*
|
1997-04-24 |
1997-06-18 |
Nycomed Imaging As |
Contrast agents
|
EP0846702B1
(de)
*
|
1996-12-09 |
2009-03-11 |
MERCK PATENT GmbH |
Löslicher, rekombinanter alphaV beta3 Adhäsionsrezeptor
|
US6596850B1
(en)
*
|
1998-01-30 |
2003-07-22 |
Ixsys, Incorporated |
Anti-αv3β3 recombinant human antibodies, nucleic acids encoding same
|
US6590079B2
(en)
|
1997-01-30 |
2003-07-08 |
Ixsys, Incorporated |
Anti-αvβ3 recombinant human antibodies, nucleic acids encoding same
|
US5837283A
(en)
|
1997-03-12 |
1998-11-17 |
The Regents Of The University Of California |
Cationic lipid compositions targeting angiogenic endothelial cells
|
US7112338B2
(en)
|
1997-03-12 |
2006-09-26 |
The Regents Of The University Of California |
Cationic liposome delivery of taxanes to angiogenic blood vessels
|
DE69828154T2
(de)
*
|
1997-03-12 |
2005-06-23 |
Smithkline Beecham Corp. |
Anti-alphavbeta3 humanizierte monoklonale antikörper
|
US5994388A
(en)
*
|
1997-03-18 |
1999-11-30 |
The Children's Medical Center Corporation |
Cytochalasin and isoindolinone derivatives as inhibitors of angiogenesis
|
WO1998041158A1
(en)
|
1997-03-19 |
1998-09-24 |
Lucid Technologies, Inc. |
Cellular surgery utilizing confocal microscopy
|
AU6954398A
(en)
*
|
1997-04-11 |
1998-11-11 |
G.D. Searle & Co. |
Antagonistic anti-avb3 integrin antibodies
|
AU6954498A
(en)
*
|
1997-04-11 |
1998-11-11 |
G.D. Searle & Co. |
Methods for using antagonistic anti-avb3 integrin antibodies
|
US6596276B1
(en)
*
|
1997-09-30 |
2003-07-22 |
Beth Israel Deaconess Medical Center |
Method for inhibiting tumor angiogenesis in a living subject
|
US6172256B1
(en)
*
|
1998-03-04 |
2001-01-09 |
G.D. Searle & Co. |
Chiral-β-amino acid compounds and derivatives thereof
|
US6372719B1
(en)
*
|
1998-03-04 |
2002-04-16 |
Jay Cunningham |
ανβ3 integrin antagonists in combination with chemotherapeutic agents
|
US6537520B1
(en)
|
1998-03-31 |
2003-03-25 |
Bristol-Myers Squibb Pharma Company |
Pharmaceuticals for the imaging of angiogenic disorders
|
US6548663B1
(en)
|
1998-03-31 |
2003-04-15 |
Bristol-Myers Squibb Pharma Company |
Benzodiazepine vitronectin receptor antagonist pharmaceuticals
|
CA2324555A1
(en)
|
1998-03-31 |
1999-11-18 |
Du Pont Pharmaceuticals Company |
Pharmaceuticals for the imaging of angiogenic disorders
|
US6524553B2
(en)
*
|
1998-03-31 |
2003-02-25 |
Bristol-Myers Squibb Pharma Company |
Quinolone vitronectin receptor antagonist pharmaceuticals
|
US6852318B1
(en)
|
1998-05-08 |
2005-02-08 |
The Regents Of The University Of California |
Methods for detecting and inhibiting angiogenesis
|
US6962974B1
(en)
|
1998-06-17 |
2005-11-08 |
Beth Israel Deaconess Medical Center |
Anti-angiogenic proteins and fragments and methods of use thereof
|
US6759047B1
(en)
|
1998-06-17 |
2004-07-06 |
Beth Israel Deaconess Hospital Corp. |
Anti-angiogenic proteins and methods of use thereof
|
US7387779B2
(en)
|
1998-06-17 |
2008-06-17 |
Beth Israel Deaconess Medical Center |
Anti-angiogenic proteins and fragments and methods of use thereof
|
ATE276763T1
(de)
|
1998-07-13 |
2004-10-15 |
Univ Texas |
Verwendung von antikörper gegen aminophospholipide zur krebsbehandlung
|
RU2167425C2
(ru)
*
|
1998-07-17 |
2001-05-20 |
Малышев Игорь Юрьевич |
Способ определения белков
|
US6164281A
(en)
*
|
1998-07-20 |
2000-12-26 |
Zhao; Iris Ginron |
Method of making and/or treating diseases characterized by neovascularization
|
AU3449899A
(en)
*
|
1998-08-13 |
2000-03-06 |
G.D. Searle & Co. |
Multivalent avb3 and Metastasis-Associated Receptor Ligands
|
US6979697B1
(en)
*
|
1998-08-21 |
2005-12-27 |
Point Therapeutics, Inc. |
Regulation of substrate activity
|
US6703050B1
(en)
*
|
1998-09-04 |
2004-03-09 |
The Regents Of The University Of Michigan |
Methods and compositions for the prevention or treatment of cancer
|
US6537554B1
(en)
|
1998-09-10 |
2003-03-25 |
Curagen Corporation |
Nucleotide sequences and amino acid sequences of secreted proteins involved in angiogenesis
|
US6248327B1
(en)
|
1998-09-11 |
2001-06-19 |
Vanderbilt University |
Modulation of endothelial cell surface receptor activity in the regulation of angiogenesis
|
US7176289B1
(en)
|
1998-09-11 |
2007-02-13 |
Vanderbilt University |
Modulation of endothelial cell surface receptor activity in the regulation of angiogenesis
|
US20030202977A1
(en)
*
|
1998-11-16 |
2003-10-30 |
New York University |
Treatment of osteoarthritis
|
US6235877B1
(en)
|
1999-08-04 |
2001-05-22 |
Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. |
Peptido-mimetic compounds containing RGD sequence useful as integrin inhibitors
|
EP1135153B1
(de)
*
|
1998-11-20 |
2005-04-27 |
Genentech, Inc. |
Verwendung von eph-rezeptor-antagonisten und agonisten zur behandlung von vaskulären krankheiten
|
US6339062B1
(en)
*
|
1998-11-23 |
2002-01-15 |
Inkine Pharmaceutical Company, Inc. |
Retroinverso polypeptides that mimic or inhibit thrombospondin activity
|
US6160099A
(en)
*
|
1998-11-24 |
2000-12-12 |
Jonak; Zdenka Ludmila |
Anti-human αv β3 and αv β5 antibodies
|
US6511649B1
(en)
*
|
1998-12-18 |
2003-01-28 |
Thomas D. Harris |
Vitronectin receptor antagonist pharmaceuticals
|
US6569402B1
(en)
|
1998-12-18 |
2003-05-27 |
Bristol-Myers Squibb Pharma Company |
Vitronectin receptor antagonist pharmaceuticals
|
US6558649B1
(en)
|
1998-12-18 |
2003-05-06 |
Bristol-Myers Squibb Pharma Company |
Vitronectin receptor antagonist pharmaceuticals
|
US6794518B1
(en)
|
1998-12-18 |
2004-09-21 |
Bristol-Myers Squibb Pharma Company |
Vitronectin receptor antagonist pharmaceuticals
|
JP2002532440A
(ja)
|
1998-12-18 |
2002-10-02 |
デュポン ファーマシューティカルズ カンパニー |
ビトロネクチン受容体拮抗剤薬剤
|
BR9916518A
(pt)
*
|
1998-12-23 |
2002-01-29 |
Searle & Co |
Método para tratar ou prevenir um distúrbio de neoplasia em um mamìfero em necessidade de tal tratamento ou prevenção, e, combinação compreendendo um inibidor de ciclooxigenase-2 e um ou mais agentes anti-neoplásticos
|
US20050281821A1
(en)
*
|
1999-01-06 |
2005-12-22 |
Flavia Pernasetti |
Method and composition for angiogenesis inhibition
|
US6521593B1
(en)
*
|
1999-02-01 |
2003-02-18 |
Childrens Hospital Los Angeles |
Methods for inhibiting brain tumor growth
|
ATE412433T1
(de)
*
|
1999-02-12 |
2008-11-15 |
Scripps Research Inst |
Methoden zur behandlung von tumoren und metastasen unter verwendung einer anti-angiogenen und immun-therapien
|
WO2000059532A1
(en)
*
|
1999-04-01 |
2000-10-12 |
Biostratum, Inc. |
The use of domains of type iv collagen t inhibit angiogenesis an tumour growth
|
AU4982200A
(en)
*
|
1999-05-06 |
2000-11-21 |
Burnham Institute, The |
Antiangiogenic endostatin peptides, endostatin variants and methods of use
|
US6890904B1
(en)
*
|
1999-05-25 |
2005-05-10 |
Point Therapeutics, Inc. |
Anti-tumor agents
|
US6531580B1
(en)
|
1999-06-24 |
2003-03-11 |
Ixsys, Inc. |
Anti-αvβ3 recombinant human antibodies and nucleic acids encoding same
|
US6685914B1
(en)
*
|
1999-09-13 |
2004-02-03 |
Bristol-Myers Squibb Pharma Company |
Macrocyclic chelants for metallopharmaceuticals
|
US20080038274A1
(en)
*
|
1999-09-23 |
2008-02-14 |
Foster Keith A |
Inhibition of secretion from non-neuronal cells
|
JP2003509468A
(ja)
*
|
1999-09-23 |
2003-03-11 |
ザ・スクリプス・リサーチ・インステイチユート |
癒着形成を阻害する方法および組成物
|
AU1072701A
(en)
*
|
1999-10-04 |
2001-05-10 |
Chiron Corporation |
Cd40 antagonist for treating psoriasis
|
AU781444B2
(en)
|
1999-12-22 |
2005-05-26 |
Scripps Research Institute, The |
Angiogenesis and vascular permeability modulators and inhibitors
|
US7740841B1
(en)
|
2000-01-28 |
2010-06-22 |
Sunnybrook Health Science Center |
Therapeutic method for reducing angiogenesis
|
HUP0300544A3
(en)
*
|
2000-02-03 |
2005-03-29 |
Eisai Co Ltd |
Pharmaceutical compositions containing integrin expression inhibitors
|
US7361643B2
(en)
|
2000-02-09 |
2008-04-22 |
University Of Puerto Rico |
Methods for inhibiting angiogenesis
|
WO2001058931A1
(en)
*
|
2000-02-11 |
2001-08-16 |
Duke University |
Method of treating disorders of the eye
|
US6573096B1
(en)
*
|
2000-04-01 |
2003-06-03 |
The Research Foundation At State University Of New York |
Compositions and methods for inhibition of cancer invasion and angiogenesis
|
US6835806B2
(en)
|
2000-04-03 |
2004-12-28 |
Phoenix Pharmaceuticals, Inc. |
Cell growth regulation system
|
DK1272507T3
(da)
|
2000-04-12 |
2005-10-03 |
Amersham Health As |
Integrinbindende peptidderivater
|
US10293056B1
(en)
*
|
2000-05-24 |
2019-05-21 |
Board Of Regents, The University Of Texas System |
Methods and compositions for non-viral gene therapy for treatment of hyperproliferative diseases
|
US7163681B2
(en)
|
2000-08-07 |
2007-01-16 |
Centocor, Inc. |
Anti-integrin antibodies, compositions, methods and uses
|
US7288390B2
(en)
*
|
2000-08-07 |
2007-10-30 |
Centocor, Inc. |
Anti-dual integrin antibodies, compositions, methods and uses
|
US20030104573A1
(en)
*
|
2000-09-11 |
2003-06-05 |
Shimkets Richard A. |
Nucleotide sequences and amino acid sequences of secreted proteins involved in angiogenesis
|
NO20004795D0
(no)
|
2000-09-26 |
2000-09-26 |
Nycomed Imaging As |
Peptidbaserte forbindelser
|
WO2002028355A2
(en)
*
|
2000-10-02 |
2002-04-11 |
The Scripps Research Institute |
Methods and compositions for enhancing angiogenesis
|
US6632835B2
(en)
|
2001-02-22 |
2003-10-14 |
Nanodesign Inc. |
Dibenzo[c]chromen-6-one derivatives as anti-cancer agents
|
DE10109136A1
(de)
*
|
2001-02-26 |
2002-09-12 |
Cytotools Gmbh |
Mittel, die die Apoptose bei an der Wundheilung beteiligten Zellen inhibieren
|
JP2004536786A
(ja)
*
|
2001-03-02 |
2004-12-09 |
メディミューン,インコーポレイテッド |
インテグリンαvβ3拮抗薬を他の予防薬もしくは治療薬と組み合わせて投与することによる炎症性疾患または自己免疫疾患の予防または治療方法
|
KR100861466B1
(ko)
|
2001-04-24 |
2008-10-02 |
메르크 파텐트 게엠베하 |
항혈관형성제 및 TNFα를 이용한 병용 요법
|
SE0101854L
(sv)
*
|
2001-05-28 |
2002-11-29 |
Bioneris Ab |
Användning av en förening med en negativt laddad region av grupper för behandling av restenos.
|
US7829087B2
(en)
*
|
2001-07-09 |
2010-11-09 |
Elan Pharmaceuticals, Inc. |
Methods of treating cognitive impairment
|
AU2002312566A1
(en)
*
|
2001-07-09 |
2003-01-29 |
Elan Pharmaceuticals, Inc. |
Methods of inhibiting amyloid toxicity
|
PL207834B1
(pl)
|
2001-07-10 |
2011-02-28 |
Ge Healthcare As |
Związki na bazie peptydów, ich zastosowanie oraz zawierająca je kompozycja farmaceutyczna
|
CA2451942A1
(en)
*
|
2001-07-27 |
2003-02-13 |
Munirathinam Sundaramoorthy |
Crystallized structure of type iv collagen nc1 domain hexamer
|
US20060014697A1
(en)
*
|
2001-08-22 |
2006-01-19 |
Travis Mickle |
Pharmaceutical compositions for prevention of overdose or abuse
|
US20030119834A1
(en)
*
|
2001-09-05 |
2003-06-26 |
Bamdad Cynthia C. |
Compositions and methods of treatment of cancer
|
JP4750360B2
(ja)
|
2001-10-22 |
2011-08-17 |
ザ スクリプス リサーチ インスティチュート |
抗体ターゲッティング化合物
|
KR20040091002A
(ko)
*
|
2002-02-14 |
2004-10-27 |
메르크 파텐트 게엠베하 |
안질환을 치료하기 위한 방법 및 조성물
|
EP1474168A1
(de)
*
|
2002-02-15 |
2004-11-10 |
Richard Brunner |
7s immunglobulin zur behandlung der gefässneubildung in der aderhaut des auges
|
CA2478239A1
(en)
*
|
2002-03-04 |
2003-09-18 |
Medimmune, Inc. |
The prevention or treatment of cancer using integrin alphavbeta3 antagonists in combination with other agents
|
EP1487489A4
(de)
*
|
2002-03-04 |
2008-10-01 |
Medimmune Inc |
VERFAHREN ZUR PRÄVENTION ODER BEHANDLUNG VON ERKRANKUNGEN DURCH VERABREICHUNG EINES INTEGRIN avb3 ANTAGONISTEN IN KOMBINATION MIT EINEM HMG-CoA REDUKTASE-HEMMER ODER EINEM BISPHOSPHONAT
|
WO2003086458A1
(en)
|
2002-04-12 |
2003-10-23 |
Medimmune, Inc. |
Recombinant anti-interleukin-9 antibodies
|
ATE491725T1
(de)
|
2002-07-15 |
2011-01-15 |
Univ Texas |
Antikörper mit bindung an anionische phospholipide und aminophospholipide und ihre verwendung bei der behandlung von virusinfektionen
|
GB0217018D0
(en)
*
|
2002-07-23 |
2002-08-28 |
Bioacta Ltd |
Peptide 1
|
US7888389B2
(en)
*
|
2002-07-23 |
2011-02-15 |
The Regents Of The University Of Michigan |
Tetrapropylammonium tetrathiomolybdate and related compounds for anti-angiogenic therapies
|
CA2506668C
(en)
|
2002-11-19 |
2014-08-19 |
Drg International, Inc. |
Diagnostic method for diseases by screening for hepcidin in human or animal tissues, blood or body fluids and therapeutic uses therefor
|
US8017737B2
(en)
|
2002-11-19 |
2011-09-13 |
Hasan Kulaksiz |
Diagnostic methods for diseases by screening for hepcidin in human or animal tissues, blood or body fluids; monoclonal antibodies specific to human hepcidin and associated uses therefor
|
US7411048B2
(en)
|
2002-11-19 |
2008-08-12 |
Drg International, Inc. |
Diagnostic method for diseases by screening for hepcidin in human or animal tissues, blood or body fluids
|
US20040208869A1
(en)
*
|
2003-01-30 |
2004-10-21 |
Medimmune, Inc. |
Uses of anti-integrin alphanubeta3 antibody formulations
|
EP1596884A2
(de)
*
|
2003-01-30 |
2005-11-23 |
Medimmune, Inc. |
Verwendung von integrin alphabeta3 antagonisten
|
WO2004069873A2
(en)
|
2003-02-06 |
2004-08-19 |
Tripep Ab |
Antigen/antibody or ligand/receptor glycosylated specificity exchangers
|
US7335359B2
(en)
*
|
2003-02-06 |
2008-02-26 |
Tripep Ab |
Glycosylated specificity exchangers
|
KR20110094361A
(ko)
*
|
2003-04-11 |
2011-08-23 |
메디뮨 엘엘씨 |
재조합 il9 항체 및 그의 용도
|
EP1616009A2
(de)
*
|
2003-04-18 |
2006-01-18 |
The University of British Columbia |
Verfahren zur behandlung von angiogenischen erkrankungen
|
CA2525969A1
(en)
*
|
2003-05-16 |
2005-02-24 |
Receptor Biologix, Inc. |
Intron fusion proteins, and methods of identifying and using same
|
BRPI0410875A
(pt)
*
|
2003-05-30 |
2006-07-04 |
Centocor Inc |
método de inibição do crescimento de tumor com anticorpos de fator antitecido
|
US9708410B2
(en)
|
2003-05-30 |
2017-07-18 |
Janssen Biotech, Inc. |
Anti-tissue factor antibodies and compositions
|
US7605235B2
(en)
|
2003-05-30 |
2009-10-20 |
Centocor, Inc. |
Anti-tissue factor antibodies and compositions
|
US20050170455A1
(en)
*
|
2003-06-20 |
2005-08-04 |
Qun-Yong Zhou |
Novel prokineticin receptor isoforms and methods of use
|
JP2007512347A
(ja)
*
|
2003-11-26 |
2007-05-17 |
デューク・ユニバーシティー |
緑内障を予防するかまたは治療する方法
|
CA2553690C
(en)
|
2004-01-22 |
2016-05-24 |
Sung Lan Hsia |
Topical co-enzyme q10 formulations and methods of use
|
US7271245B2
(en)
*
|
2004-02-13 |
2007-09-18 |
The Scripps Research Institute |
Methods and compositions for inhibition of metastasis
|
AU2005215017A1
(en)
*
|
2004-02-17 |
2005-09-01 |
Cancervax Corporation |
Method and composition for angiogenesis inhibition
|
US7351739B2
(en)
*
|
2004-04-30 |
2008-04-01 |
Wellgen, Inc. |
Bioactive compounds and methods of uses thereof
|
US8187595B2
(en)
*
|
2004-05-07 |
2012-05-29 |
The University Of North Carolina At Chapel Hill |
Monoclonal antibodies for enhancing or inhibiting insulin-like growth factor-I
|
JP4928443B2
(ja)
*
|
2004-05-07 |
2012-05-09 |
ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル |
インスリン様成長因子iを増強または阻害するための方法
|
AU2005245896A1
(en)
*
|
2004-05-14 |
2005-12-01 |
Receptor Biologix, Inc. |
Cell surface receptor isoforms and methods of identifying and using the same
|
WO2005117954A2
(en)
|
2004-06-04 |
2005-12-15 |
The Scripps Research Institute |
Compositions and methods for treatment of neovascular diseases
|
US7470521B2
(en)
*
|
2004-07-20 |
2008-12-30 |
Critical Therapeutics, Inc. |
RAGE protein derivatives
|
US20060029544A1
(en)
*
|
2004-08-06 |
2006-02-09 |
The Regents Of The University Of California Office Of Technology Transfer |
Receptor-binding cyclic peptides and methods of use
|
AU2005277567A1
(en)
*
|
2004-08-16 |
2006-03-02 |
Medimmune, Llc |
Integrin antagonists with enhanced antibody dependent cell-mediated cytotoxicity activity
|
CA2585717A1
(en)
|
2004-10-27 |
2006-05-04 |
Medimmune Inc. |
Modulation of antibody specificity by tailoring the affinity to cognate antigens
|
KR100679100B1
(ko)
*
|
2004-10-29 |
2007-02-06 |
엘지.필립스 엘시디 주식회사 |
수평 전계 인가형 액정 표시 패널 및 그 제조방법
|
JP2008525424A
(ja)
*
|
2004-12-23 |
2008-07-17 |
モルメド エスピーエー |
複合生成物
|
WO2006111925A2
(en)
*
|
2005-04-18 |
2006-10-26 |
Sloan-Kettering Institute For Cancer Research |
Inhibition of tumorigenesis by inhibition of a6b4 integrin
|
US20090170769A1
(en)
*
|
2005-05-13 |
2009-07-02 |
Pei Jin |
Cell surface receptor isoforms and methods of identifying and using the same
|
US20060286148A1
(en)
*
|
2005-05-18 |
2006-12-21 |
Ppd, Inc. |
Method of forming implants
|
US8354106B2
(en)
|
2005-06-16 |
2013-01-15 |
The Feinstein Institute For Medical Research |
Antibodies against HMGB1 and fragments thereof
|
EP1893647A2
(de)
|
2005-06-23 |
2008-03-05 |
MedImmune, Inc. |
Antikörperformulierungen mit optimierten aggregations- und fragmentierungsprofilen
|
WO2007024921A2
(en)
*
|
2005-08-24 |
2007-03-01 |
Cell Matrix |
Combination therapies for inhibiting integrin-extracellular matrix interactions
|
JP2009523813A
(ja)
|
2006-01-18 |
2009-06-25 |
メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング |
癌を治療するためにインテグリンのリガンドを使用する特異的な治療法
|
KR101049505B1
(ko)
|
2006-01-19 |
2011-07-15 |
아이진 주식회사 |
펩타이드를 유효성분으로 하는 혈관 관련 질환 치료제조성물
|
US20100055093A1
(en)
*
|
2006-06-12 |
2010-03-04 |
Receptor Biologix Inc. |
Pan-cell surface receptor-specific therapeutics
|
WO2008008373A2
(en)
|
2006-07-11 |
2008-01-17 |
Arubor Corp |
Rhinosinusitis prevention and therapy with proinflammatory cytokine inhibitors
|
JP2010500360A
(ja)
|
2006-08-10 |
2010-01-07 |
アルボア コーポレーション |
炎症性サイトカイン阻害剤による下気道炎症疾患の局所療法
|
WO2008045252A2
(en)
|
2006-10-04 |
2008-04-17 |
The Board Of Trustees Of The Leland Stanford Junior University |
Engineered integrin binding peptides
|
KR20090108713A
(ko)
|
2007-01-18 |
2009-10-16 |
메르크 파텐트 게엠베하 |
인테그린 리간드를 사용하는 암치료용 특이적 요법 및 의약
|
EP2025685B1
(de)
*
|
2007-08-15 |
2013-06-19 |
Canadian Blood Services |
Monoklonale Antikörper gegen BETA3-Integrine
|
KR20100082775A
(ko)
*
|
2007-10-16 |
2010-07-19 |
심포젠 에이/에스 |
최적화된 her1 및 her3 멀티머를 포함하는 조성물 및 그것의 사용 방법
|
NZ586053A
(en)
|
2007-11-09 |
2012-09-28 |
Peregrine Pharmaceuticals Inc |
Anti-vegf antibody compositions and methods
|
EP2285960B1
(de)
|
2008-05-08 |
2015-07-08 |
Asuragen, INC. |
Zusammensetzungen und verfahren in zusammenhang mit der mirna-184modulation von neovaskularisation oder angiogenese
|
AU2009274512A1
(en)
|
2008-07-25 |
2010-01-28 |
The Regents Of The University Of Colorado |
Clip inhibitors and methods of modulating immune function
|
DK2352817T3
(en)
|
2008-10-31 |
2016-04-18 |
Univ Louisville Res Found |
OLFACTORY EPITAL DERIVATIVE STEM CELLS AND PROCEDURES FOR USE THEREOF
|
EP2374002A1
(de)
|
2008-12-23 |
2011-10-12 |
GE Healthcare UK Limited |
Anwendung einer auf 99mtc-peptid basierenden verbindung als knochenmark-bildgebungsmittel
|
JP2012517447A
(ja)
|
2009-02-10 |
2012-08-02 |
ザ スクリプス リサーチ インスティチュート |
化学的にプログラムされたワクチン接種法
|
NZ597339A
(en)
|
2009-05-25 |
2013-10-25 |
Merck Patent Gmbh |
Continuous administration of cilengitide in cancer treatments
|
FR2949782B1
(fr)
*
|
2009-09-04 |
2015-10-16 |
Isp Investments Inc |
Peptide activateur de la transglutaminase et composition cosmetique ou pharmaceutique le contenant.
|
US8778888B2
(en)
*
|
2009-11-06 |
2014-07-15 |
The Board Of Trustees Of The Leland Stanford Junior University |
Cystine knot peptides binding to alpha IIb beta 3 integrins and methods of use
|
WO2012007137A1
(en)
|
2010-07-16 |
2012-01-19 |
Merck Patent Gmbh |
Peptide for use in the treatment of breast cancer and/or bone metastases
|
CN103347540B
(zh)
|
2011-02-11 |
2016-05-25 |
默克专利股份公司 |
用于治疗前列腺癌的抗-α-v整联蛋白抗体
|
US8722044B2
(en)
|
2011-03-15 |
2014-05-13 |
Janssen Biotech, Inc. |
Human tissue factor antibody and uses thereof
|
RU2531502C2
(ru)
*
|
2011-08-09 |
2014-10-20 |
Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Московский государственный университет имени М.В. Ломоносова" (МГУ) |
Способ повышения ангиогенной активности стромальных клеток жировой ткани
|
RU2481115C1
(ru)
*
|
2011-10-13 |
2013-05-10 |
Общество с ограниченной ответственностью Научно-Производственное Объединение "Тюменькриобанк" |
Средство для заживления ран "целльгель", способ его получения и способ лечения ран различной этиологии полученным средством
|
US9775803B2
(en)
|
2011-10-19 |
2017-10-03 |
Samsung Electronics Co., Ltd. |
Liposome comprising elastin-like polypeptide and tumor cell targeting material and use thereof
|
US20140350087A9
(en)
|
2012-03-22 |
2014-11-27 |
Halozyme, Inc. |
Oncovector Nucleic Acid Molecules and Methods of Use
|
CN104968796A
(zh)
*
|
2012-06-07 |
2015-10-07 |
庄伟哲 |
经修饰纤维黏连蛋白片段或变体及其用途
|
WO2014036385A1
(en)
|
2012-08-31 |
2014-03-06 |
The University Of North Carolina At Chapel Hill |
Monoclonal antibodies for enhancing or inhibiting insulin-like growth factor 1 (igf-1)
|
WO2014063012A1
(en)
|
2012-10-19 |
2014-04-24 |
The Board Of Trustees Of The Leland Stanford Junior University |
Conjugated knottin mini-proteins containing non-natural amino acids
|
EP2928871B1
(de)
|
2012-12-07 |
2017-02-01 |
Council of Scientific & Industrial Research |
Histidinylierte kationische amphiphile, verfahren zu ihrer herstellung und ihre liposomale formulierung
|
JP6457999B2
(ja)
|
2013-03-14 |
2019-01-23 |
ザ チルドレンズ メディカル センター コーポレーション |
処置に関してがんの対象を識別するためのcd36の使用
|
NZ742238A
(en)
|
2015-11-23 |
2023-11-24 |
Merck Patent Gmbh |
Anti-alpha-v integrin antibody for the treatment of fibrosis and/or fibrotic disorders
|
US10786471B2
(en)
|
2017-02-06 |
2020-09-29 |
Massachusetts Institute Of Technology |
Methods and products related to glutaminase inhibitors
|
EP3600422B1
(de)
|
2017-03-31 |
2023-10-18 |
The Regents of the University of California |
Zusammensetzungen zur verwendung in dem verfahren zum abzielen und töten von alpha-v beta-3-positiven krebsstammzellen (cscs) und in der behandlung von arzneimittelresistenten tumoren
|
KR102171433B1
(ko)
*
|
2018-05-25 |
2020-11-02 |
고려대학교 산학협력단 |
조직 재생을 위한 Substance P 펩타이드가 고정된 피브린 젤 및 이의 제조방법
|
CN113557246B
(zh)
*
|
2019-07-24 |
2023-09-01 |
韩国基础科学支援研究院 |
靶向αvβ3整联蛋白的单域抗体
|
MX2022000990A
(es)
*
|
2019-08-02 |
2022-02-16 |
Univ California |
Composiciones y metodos que se dirigen y eliminan celulas madre cancerosas (csc) positivas para alfa-v beta-3 (av?3) y tratan canceres resistentes a farmacos y metastasicos.
|
IL300930A
(en)
|
2020-08-27 |
2023-04-01 |
Enosi Therapeutics Corp |
Methods and compositions for the treatment of autoimmune diseases and cancer
|